Suven Life Science secures product patent in Canada

03 Apr 2018 Evaluate

Suven Life Sciences has secured one product patent from Canada corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2033.

The granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

166.00 -4.15 (-2.44%)
08-Dec-2025 11:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.10
Dr. Reddys Lab 1275.60
Cipla 1510.10
Zydus Lifesciences 932.00
Lupin 2086.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×